Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Keros Therapeutics, Inc. (KROS : NSDQ)
 
 • Company Description   
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA.

Number of Employees: 60

 
 • Price / Volume Information   
Yesterday's Closing Price: $44.07 Daily Weekly Monthly
20 Day Moving Average: 139,560 shares
Shares Outstanding: 24.03 (millions)
Market Capitalization: $1,059.22 (millions)
Beta: 1.11
52 Week High: $68.29
52 Week Low: $28.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -28.90% -22.09%
12 Week -15.40% -8.20%
Year To Date -24.68% -10.43%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER
-
LEXINGTON,MA 02421
USA
ph: 617-314-6297
fax: -
mbiega@soleburytrout.com http://www.kerostx.com
 
 • General Corporate Information   
Officers
Jasbir Seehra - Chief Executive Officer
Keith Regnante - Chief Financial Officer
Carl Gordon - Director
Mary Ann Gray - Director
Julius Knowles - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 492327101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 24.03
Most Recent Split Date: (:1)
Beta: 1.11
Market Capitalization: $1,059.22 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.09 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.55 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.74
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -48.53%
vs. Previous Quarter: -236.67%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -29.13
12/31/21 - -24.85
09/30/21 - -25.92
ROA
03/31/22 - -27.83
12/31/21 - -23.82
09/30/21 - -24.98
Current Ratio
03/31/22 - 19.85
12/31/21 - 21.23
09/30/21 - 20.52
Quick Ratio
03/31/22 - 19.85
12/31/21 - 21.23
09/30/21 - 20.52
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -323.80
12/31/21 - -282.25
09/30/21 - -62,468.00
Book Value
03/31/22 - 9.30
12/31/21 - 10.39
09/30/21 - 9.34
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©